PELP1 oncogenic functions involve alternative splicing via PRMT6

Molecular Oncology

Volumn 8, Issue 2, 2014, Pages 389-400

  Mann, Monica ^a   Zou, Yi ^b   Chen, Yidong ^b   Brann, Darrell ^c   Vadlamudi, Ratna ^a,b  

^a University of Texas Health Science Center   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c AUGUSTA UNIVERSITY   (United States)

Author keywords

Alternative splicing; Breast cancer; Epigenetics; PELP1; PRMT6

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PEPTIDES AND PROTEINS; POLYCYTIDYLIC ACID; PROLINE GLUTAMIC ACID AND LEUCINE RICH PROTEIN 1; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 6; UNCLASSIFIED DRUG; HISTONE H3; HISTONE METHYLTRANSFERASE; ONCOPROTEIN; PROTEIN PRMT6; RNA; TRANSCRIPTOME; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN 189;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; GENOME ANALYSIS; HISTONE METHYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RNA SEQUENCE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CANCER GROWTH; CARCINOGENESIS; DEMETHYLATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE FUNCTION; PROLINE GLUTAMIC ACID AND LEUCINE RICH PROTEIN 1 GENE; PROTEIN FUNCTION; PROTEIN RNA BINDING; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION;

ALTERNATIVE SPLICING; BREAST CANCER; EPIGENETICS; PELP1; PRMT6;

ALTERNATIVE SPLICING; BREAST NEOPLASMS; CELL LINE, TUMOR; CO-REPRESSOR PROTEINS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROTEIN-ARGININE N-METHYLTRANSFERASES; RECEPTORS, ESTROGEN; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84894324359     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.12.012     Document Type: Article

References (51)

1. Anders, S., HTSeq: Analysing High-throughput Sequencing Data with Python.
2. Anders S., Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010, 11:R106.
3. Auboeuf D., Honig A., Berget S.M., O'Malley B.W. Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science (New York, N.Y.) 2002, 298:416-419.
4. Auboeuf D., Dowhan D.H., Dutertre M., Martin N., Berget S.M., O'Malley B.W. A subset of nuclear receptor coregulators act as coupling proteins during synthesis and maturation of RNA transcripts. Mol. Cell. Biol. 2005, 25:5307-5316.
5. Balasenthil S., Vadlamudi R.K. Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J.Biol. Chem. 2003, 278:22119-22127.
6. Carrillo Oesterreich F., Preibisch S., Neugebauer K.M. Global analysis of nascent RNA reveals transcriptional pausing in terminal exons. Mol. Cell 2010, 40:571-581.
7. Castle C.D., Cassimere E.K., Denicourt C. LAS1L interacts with the mammalian Rix1 complex to regulate ribosome biogenesis. Mol. Biol. Cell 2012, 23:716-728.
8. Chakravarty D., Nair S.S., Santhamma B., Nair B.C., Wang L., Bandyopadhyay A., Agyin J.K., Brann D., Sun L.Z., Yeh I.T., Lee F.Y., Tekmal R.R., Kumar R., Vadlamudi R.K. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res. 2010, 70:4092-4101.
9. Chakravarty D., Roy S.S., Babu C.R., Dandamudi R., Curiel T.J., Vivas-Mejia P., Lopez-Berestein G., Sood A.K., Vadlamudi R.K. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin. Cancer Res.: An Off. J. Am. Assoc. Cancer Res. 2011, 17:2250-2259.
10. Chen H.C., Lin W.C., Tsay Y.G., Lee S.C., Chang C.J. An RNA helicase, DDX1, interacting with poly(A) RNA and heterogeneous nuclear ribonucleoprotein K. J.Biol. Chem. 2002, 277:40403-40409.
11. Cheng D., Cote J., Shaaban S., Bedford M.T. The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. Mol. Cell 2007, 25:71-83.
12. Choi H.S., Hwang C.K., Song K.Y., Law P.Y., Wei L.N., Loh H.H. Poly(C)-binding proteins as transcriptional regulators of gene expression. Biochem. Biophys. Res. Commun. 2009, 380:431-436.
13. Cortez V., Mann M., Tekmal S., Suzuki T., Miyata N., Rodriguez-Aguayo C., Lopez-Berestein G., Sood A.K., Vadlamudi R.K. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res.: BCR 2012, 14:R108.
14. Cote J., Boisvert F.M., Boulanger M.C., Bedford M.T., Richard S. Sam68 RNA binding protein is an invivo substrate for protein arginine N-methyltransferase 1. Mol. Biol. Cell 2003, 14:274-287.
15. Dowhan D.H., Harrison M.J., Eriksson N.A., Bailey P., Pearen M.A., Fuller P.J., Funder J.W., Simpson E.R., Leedman P.J., Tilley W.D., Brown M.A., Clarke C.L., Muscat G.E. Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocr. Relat. Cancer 2012, 19:509-526.
16. Finkbeiner E., Haindl M., Muller S. The SUMO system controls nucleolar partitioning of a novel mammalian ribosome biogenesis complex. EMBO J. 2011, 30:1067-1078.
17. Friesen W.J., Massenet S., Paushkin S., Wyce A., Dreyfuss G. SMN, the product of the spinal muscular atrophy gene, binds preferentially to dimethylarginine-containing protein targets. Mol. Cell 2001, 7:1111-1117.
18. Fu X.D. Specific commitment of different pre-mRNAs to splicing by single SR proteins. Nature 1993, 365:82-85.
19. Girard B.J., Daniel A.R., Lange C.A., Ostrander J.H. PELP1: a review of PELP1 interactions, signaling, and biology. Mol. Cell Endocrinol. 2013, 382:642-651.
20. Gonugunta V.K., Nair B.C., Rajhans R., Sareddy G.R., Nair S.S., Vadlamudi R.K. Regulation of rDNA transcription by proto-oncogene PELP1. PloS One 2011, 6:e21095.
21. Gururaj A.E., Peng S., Vadlamudi R.K., Kumar R. Estrogen induces expression of BCAS3, a novel estrogen receptor-alpha coactivator, through proline-, glutamic acid-, and leucine-rich protein-1 (PELP1). Mol. Endocrinol. (Baltimore, Md.) 2007, 21:1847-1860.
22. Habashy H.O., Powe D.G., Rakha E.A., Ball G., Macmillan R.D., Green A.R., Ellis I.O. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res. Treat. 2010, 120:603-612.
23. Harrison M.J., Tang Y.H., Dowhan D.H. Protein arginine methyltransferase 6 regulates multiple aspects of gene expression. Nucl. Acids Res. 2010, 38:2201-2216.
24. Herrmann F., Bossert M., Schwander A., Akgun E., Fackelmayer F.O. Arginine methylation of scaffold attachment factor A by heterogeneous nuclear ribonucleoprotein particle-associated PRMT1. J.Biol. Chem. 2004, 279:48774-48779.
25. Ip J.Y., Schmidt D., Pan Q., Ramani A.K., Fraser A.G., Odom D.T., Blencowe B.J. Global impact of RNA polymerase II elongation inhibition on alternative splicing regulation. Genome Res. 2011, 21:390-401.
26. Konig H., Ponta H., Herrlich P. Coupling of signal transduction to alternative pre-mRNA splicing by a composite splice regulator. EMBO J. 1998, 17:2904-2913.
27. Kornblihtt A.R., Schor I.E., Allo M., Dujardin G., Petrillo E., Munoz M.J. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat. Rev. Mol. Cell Biol. 2013, 14:153-165.
28. Kramer A. The structure and function of proteins involved in mammalian pre-mRNA splicing. Annu. Rev. Biochem. 1996, 65:367-409.
29. Kumar R., Zhang H., Holm C., Vadlamudi R.K., Landberg G., Rayala S.K. Extranuclear coactivator signaling confers insensitivity to tamoxifen. Clin. Cancer Res. An Off. J. Am. Assoc. Cancer Res. 2009, 15:4123-4130.
30. Limm K., Ott C., Wallner S., Mueller D.W., Oefner P., Hellerbrand C., Bosserhoff A.K. Deregulation of protein methylation in melanoma. Eur. J. Cancer (Oxford, Engl.: 1990) 2013, 49:1305-1313.
31. Lin S., Coutinho-Mansfield G., Wang D., Pandit S., Fu X.D. The splicing factor SC35 has an active role in transcriptional elongation. Nat. Struct. Mol. Biol. 2008, 15:819-826.
32. Mann M., Cortez V., Vadlamudi R. PELP1 oncogenic functions involve CARM1 regulation. Carcinogenesis 2004, 34:1468-1475.
33. Miranda T.B., Webb K.J., Edberg D.D., Reeves R., Clarke S. Protein arginine methyltransferase 6 specifically methylates the nonhistone chromatin protein HMGA1a. Biochem. Biophys. Res. Commun. 2005, 336:831-835.
34. Nair S.S., Mishra S.K., Yang Z., Balasenthil S., Kumar R., Vadlamudi R.K. Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res. 2004, 64:6416-6423.
35. Nair B.C., Nair S.S., Chakravarty D., Challa R., Manavathi B., Yew P.R., Kumar R., Tekmal R.R., Vadlamudi R.K. Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res. 2010, 70:7166-7175.
36. Nair S.S., Nair B.C., Cortez V., Chakravarty D., Metzger E., Schule R., Brann D.W., Tekmal R.R., Vadlamudi R.K. PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep. 2010, 11:438-444.
37. Nair B.C., Vallabhaneni S., Tekmal R.R., Vadlamudi R.K. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res.: BCR 2011, 13:R80.
38. Rajhans R., Nair S., Holden A.H., Kumar R., Tekmal R.R., Vadlamudi R.K. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res. 2007, 67:5505-5512.
39. Smith W.A., Schurter B.T., Wong-Staal F., David M. Arginine methylation of RNA helicase a determines its subcellular localization. J.Biol. Chem. 2004, 279:22795-22798.
40. Tang S., Han H., Bajic V.B. ERGDB: estrogen responsive genes database. Nucl. Acids Res. 2004, 32.
41. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., Abraham J.A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J.Biol. Chem. 1991, 266:11947-11954.
42. Trapnell C., Pachter L., Salzberg S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinform. (Oxford, England) 2009, 25:1105-1111.
43. Vadlamudi R.K., Kumar R. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl. Recep. Signal. 2007, 5:e004.
44. Vadlamudi R.K., Wang R.A., Mazumdar A., Kim Y., Shin J., Sahin A., Kumar R. Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J.Biol. Chem. 2001, 276:38272-38279.
45. Vallabhaneni S., Nair B.C., Cortez V., Challa R., Chakravarty D., Tekmal R.R., Vadlamudi R.K. Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res. Treat. 2011, 130:377-385.
46. Venables J.P., Klinck R., Koh C., Gervais-Bird J., Bramard A., Inkel L., Durand M., Couture S., Froehlich U., Lapointe E., Lucier J.F., Thibault P., Rancourt C., Tremblay K., Prinos P., Chabot B., Elela S.A. Cancer-associated regulation of alternative splicing. Nature Struct. Mol. Biol. 2009, 16:670-676.
47. Wellmann S., Taube T., Paal K., Graf V.E.H., Geilen W., Seifert G., Eckert C., Henze G., Seeger K. Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology. Clin. Chem. 2001, 47:654-660.
48. Wu J.Y., Maniatis T. Specific interactions between proteins implicated in splice site selection and regulated alternative splicing. Cell 1993, 75:1061-1070.
49. Xu Q., Lee C. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucl. Acid Res. 2003, 31:5635-5643.
50. Yang L., Ravindranathan P., Ramanan M., Kapur P., Hammes S.R., Hsieh J.T., Raj G.V. Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer. Mol. Endocrinol. (Baltimore, Md.) 2012, 26:550-561.
51. Yoshimatsu M., Toyokawa G., Hayami S., Unoki M., Tsunoda T., Field H.I., Kelly J.D., Neal D.E., Maehara Y., Ponder B.A., Nakamura Y., Hamamoto R. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int. J. Cancer (Journal international du cancer) 2011, 128:562-573.